BiVictriX Therapeutics PLC (GB:BVX) has released an update.
BiVictriX Therapeutics PLC has been awarded a £0.37 million grant from Innovate UK to accelerate the development of BVX002, its novel bispecific Antibody Drug Conjugate intended to treat ovarian cancer. The grant will support the company’s non-dilutive strategy to advance R&D, enabling them to fast-track preclinical studies and the selection of a clinical lead candidate. This funding is a significant step in addressing the high unmet medical need in ovarian cancer treatment with a therapy designed to target cancer cells precisely, reducing treatment-related toxicities.
For further insights into GB:BVX stock, check out TipRanks’ Stock Analysis page.
